Among efficacy-evaluable patients with TP53 mutation and/or del(17p) alteration (n=12), ORR/CR rate was 67%/25%. Median time to response was 2.1mo (range,1.6–3.3), and median time to CR was 3.2mo (range, 1.6–10.8)….Preliminary efficacy findings show that epcoritamab SC induces high ORRs and encouraging CR rates in patients with heavily pretreated, high-risk R/R CLL.